Evidence map›Paper›PMID 34757449›Full record

ArticleEuropean radiology2022

CT-based radiomics stratification of tumor grade and TNM stage of clear cell renal cell carcinoma.

Natalie L Demirjian, Bino A Varghese, Steven Y Cen, Darryl H Hwang, Manju Aron, Imran Siddiqui, Brandon K K Fields, Xiaomeng Lei, Felix Y Yap, Marielena Rivas and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Natalie L Demirjian *College of Medicine - Tucson, University of Arizona, Tucson, AZ, USA.
Bino A Varghese *Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Steven Y CenDepartment of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Darryl H HwangDepartment of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Manju AronDepartment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Imran SiddiquiDepartment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Brandon K K FieldsScripps Mercy Hospital San Diego, San Diego, CA, USA.
Xiaomeng LeiDepartment of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Felix Y YapRadiology Associates of San Luis Obispo, Atascadero, CA, USA.
Marielena RivasDepartment of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Sharath S ReddyDepartment of Urology, Yale New Haven Hospital, New Haven, CT, USA.
Haris ZahoorDepartment of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Derek H LiuDepartment of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Mihir DesaiDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Suhn K RhieDepartment of Biochemistry and Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Inderbir S GillDepartment of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Vinay DuddalwarDepartment of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. vinay.duddalwar@med.usc.edu.ORCID http://orcid.org/0000-0002-4808-5715
University of Southern California · USRadiology Associates · USScripps Mercy Hospital · USUniversity of Arizona · USYale New Haven Hospital · US

Funding

Identification and Clinical Validation of Key Transcription Factor Isoforms Linked to Breast and Prostate Cancer Subgroups using Epigenetic TraitsK01CA229995 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2018 to 2020
$637k
Mapping regulatory elements and chromatin structures in prostate tumor subtypes at single nucleosome resolutionR21CA264637 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2021 to 2022
$420k
Reversing molecular cancer phenotypes by targeting epigenetic alterations in prostate cancerR21CA260082 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2021 to 2021
$386k
NCI NIH HHS K01 CA229995
6 · The paper itself

Abstract

objectivesTo evaluate the utility of CT-based radiomics signatures in discriminating low-grade (grades 1-2) clear cell renal cell carcinomas (ccRCC) from high-grade (grades 3-4) and low TNM stage (stages I-II) ccRCC from high TNM stage (stages III-IV).

methodsA total of 587 subjects (mean age 60.2 years ± 12.2; range 22-88.7 years) with ccRCC were included. A total of 255 tumors were high grade and 153 were high stage. For each subject, one dominant tumor was delineated as the region of interest (ROI). Our institutional radiomics pipeline was then used to extract 2824 radiomics features across 12 texture families from the manually segmented volumes of interest. Separate iterations of the machine learning models using all extracted features (full model) as well as only a subset of previously identified robust metrics (robust model) were developed. Variable of importance (VOI) analysis was performed using the out-of-bag Gini index to identify the top 10 radiomics metrics driving each classifier. Model performance was reported using area under the receiver operating curve (AUC).

resultsThe highest AUC to distinguish between low- and high-grade ccRCC was 0.70 (95% CI 0.62-0.78) and the highest AUC to distinguish between low- and high-stage ccRCC was 0.80 (95% CI 0.74-0.86). Comparable AUCs of 0.73 (95% CI 0.65-0.8) and 0.77 (95% CI 0.7-0.84) were reported using the robust model for grade and stage classification, respectively. VOI analysis revealed the importance of neighborhood operation-based methods, including GLCM, GLDM, and GLRLM, in driving the performance of the robust models for both grade and stage classification.

conclusionPost-validation, CT-based radiomics signatures may prove to be useful tools to assess ccRCC grade and stage and could potentially add to current prognostic models. Multiphase CT-based radiomics signatures have potential to serve as a non-invasive stratification schema for distinguishing between low- and high-grade as well as low- and high-stage ccRCC. KEY POINTS: • Radiomics signatures derived from clinical multiphase CT images were able to stratify low- from high-grade ccRCC, with an AUC of 0.70 (95% CI 0.62-0.78). • Radiomics signatures derived from multiphase CT images yielded discriminative power to stratify low from high TNM stage in ccRCC, with an AUC of 0.80 (95% CI 0.74-0.86). • Models created using only robust radiomics features achieved comparable AUCs of 0.73 (95% CI 0.65-0.80) and 0.77 (95% CI 0.70-0.84) to the model with all radiomics features in classifying ccRCC grade and stage, respectively.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAdultAgedAged, 80 and overArea Under CurveHumansMachine LearningMiddle AgedRetrospective StudiesTomography, X-Ray ComputedYoung AdultCarcinomaMachine learningNeoplasm gradingNeoplasm staging, radiomicsRenal cell

Identifiers

PMID34757449
OpenAlexW3212398994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.